Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has been ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

During Vertex’s third-quarter presentation, Chief Commercial Officer Duncan McKechnie cited several numbers that suggest the launch of its long-awaited, non-opioid pain reliever Journavx is trending ...

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025. Following an extensive search assisted by an ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

There's more good news than bad news for this big biotech stock. Were Vertex's Q2 results horrible? Not at all. Instead, investors reacted negatively after the big biotech company announced two ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

Renowned eyewear brand Oakley turns 50 this year. With the release of its Ellipse 50th Anniversary — an exclusive iteration that points to the brand’s disruptive innovations — Oakley is honoring the ...

Vertex's fourth Seaport building will join another across Northern Avenue. The company also has two larger buildings on Fan Pier. Gary Higgins / Boston Business ...